Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03168880 : A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer
PhasePhase 3
AgesMin: 18 Years Max: 70 Years
Eligibility
Inclusion Criteria:

1. Age 18-70 years

2. All patients with baseline clinical staging T4, N0-3, M0 or T1-4, N2-3, M0 and T3, N1,
M0 with triple negative hormone status.

3. Patients with adequate baseline marrow function defined as ANC > 1500/mm3 and Platelet
count > 1, 00,000/mm3.

4. Patients with acceptable liver function tests (normal bilirubin and AST/ALT < 2 times
the upper limit of normal) and normal renal function tests at baseline

5. Patients willing to provide informed consent

6. Patients fit for chemotherapy

Exclusion Criteria:

1. Prior excision biopsy

2. Metastatic breast cancer

3. Women with inflammatory breast cancer

4. Poor cardiac function at baseline with LVEF <40%

5. Patients with a prior history of a malignancy

6. Pregnant or lactating women.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03168880      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740